http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
김성민,이종호,김남열,안강민,최원재,최시호,차미주,이주영,황순정,장정원,명훈,최진영,서병무,정필훈,김명진 大韓顎顔面成形再建外科學會 2003 Maxillofacial Plastic Reconstructive Surgery Vol.25 No.4
Schwann cells(SCs), an important component of the peripheral nervous system, intract with nerous to mutually support growth and replication for the peripheral nerve regentation. Recently, ading SCs to the lumen of guidance channel is widely tried to improve regeneration or to make regeneration possible over otherwise irreparable gaps. however, it is not easy to isolate and multiplicate SCs as much as enough to help the axonal regeneration. For the allogeneic SCs source for tubular nerve guidance, we developed a little bit improved technique of harvesting and multiplicating SCs. by culturing dispersed dorsal root ganglia in specially designed medium with growth factors and serial processing, we repeatedlly generate relatively homogenous SC cultures. Our technique was compared with other methods of literature using immunostaining methods such as GFAP, S100, BDNF and the total SC count assessment at different time interval after primary culture.
이종호,이세영,김명진,이은진,안강민,김성민,최원재,명훈,황순정,서병무,최진영,정필훈 大韓顎顔面成形再建外科學會 2003 Maxillofacial Plastic Reconstructive Surgery Vol.25 No.2
The surgery of oral and maxillofacial area poses the risk of cranial nerve damage such as trigeminal nerve or facial nerve. Inferior alveolar nerve is prone to damage in the third molar extraction, implant installation, orthognathic surgery, open reduction and rigid fixation, and tumor ablation surgery. On the other hands,facial nerve is likely to be damaged or sacrificed with trauma or parotidectomy. In case of inferior alveolar nerve injury, the incidence is reported to be about 1.3%. The nerve function will almost recover in minimal damage, but it won't recover at last in total damage of a part of nerve unit. In latter cases, nerve regeneration in intended by allograft as nerve substitute or various route of merve condit. But the recovery with autograft is believed to be most relialbe mrthod in the rapair of long-span(longer than 15㎜)nerve defect. We have performed autologous sural nerve graft in the repair of nerve defect, which is caused by resection of benign or malignant tumor. Hereby we report the method of nerve harvesting, recovery of defected peripheral nerve and the complications of donor site with the discussion of sural nerve anatomy.
( Soung Won Jeong ),( Jae Young Jang ),( Jin Woo Choo ),( Jin Nyoung Kim ),( Soon Ha Kwon ),( Sae Hwan Lee ),( Sang Gyune Kim ),( Sang Woo Cha ),( Young Seok Kim ),( Young Deok Cho ),( Hong Soo Kim ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background/Aim: Hepatocellular carcinoma (HCC) response after transarterial chemoembolization (TACE) depends on tumor vascularization and characterization, which may be reflected in the pathognomonic pattern of HCC on contrastenhanced ultrasonography (CEUS). We assessed predictive factors on CEUS for the response of TACE. Methods: Seventeen patients with 18 HCC underwent TACE. All of the tumors were studied with CEUS before TACE. A second-generation echo-enhancer (Sono Vue; Bracco, Milan, Italy) and a low mechanical index technique were used. After TACE, tumor response was classified with a score between 1 and 4 according to the percentage of remaining enhancing tumor portion (score 1; remained enhancing lesion <25%, score 2; 25%≤enhancing lesion<50%, score 3; 50%≤enhancing lesion <75%, score 4; enhancing lesion≥75%). Score 1 was defined as “good response” after TACE. Tumor size, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, presence of hypoenhanced pattern, and feeding artery to the tumor were analyzed. Results: The median size of tumor was 3.1 cm (range 1 - 14 cm). The median time of initial arterial enhancing time and arterial enhancing duration were 21 sec, and 27.5 sec, respectively. Six tumors showed strong arterial enhancement. The presence of hypoenhanced pattern were shown in 14 tumors. Fifteen tumors had feeding arteries. The number of tumor response score after TACE in all tumors were 11 tumors in score 1, 4 in score 2, 2 in score 3, and 1 in score 4. In predicting good response after TACE, initial arterial enhancing time, arterial enhancing duration, intensity of arterial enhancement, and hypoenhanced pattern did not show any significance. Presence of a feeding artery and tumor size (<5cm) were predictive factors for good response (p=0.043, p=0.047). Conclusions: The presence of a feeding artery and tumor size less than 5cm were the predictive factors for the good response of TACE on CEUS.
The Impact of Kidney Dysfunction on Mortality in Cirrhotic Patients with Acute Deterioration
( Soung Won Jeong ),( Tae Yeob Kim ),( Eileen L. Yoon ),( Do Seon Song ),( Hee Yeon Kim ),( Chang Wook Kim ),( Young Kul Jung ),( Dong Hyun Sinn ),( Sang Gyune Kim ),( Jae Young Jang ),( Won Kim ),( H 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: This study aimed to investigate short-term mortality and associated factors in cirrhotic patients with kidney dysfunction and acute deterioration. Methods: Of the 1204 cirrhotic patients experienced acute deterioration without kidney failure (defined as serum creatinine level of 2 mg/dL or above), 1094 patients (male 815, mean age 55.8 years) were retrospective consecutively collected during 2013. Kidney dysfunction was defined by serum creatinine levels from 1.2 to 1.9 mg/dL at admission based on retrospective KACLiF [Korean Acute-on-Chronic Liver Failure (ACLF)] study. Baseline characteristics and short-term mortality according to the presence of kidney dysfucntion were analyzed. Independent risk factors for 90-day mortality in patients with kidney dysfunction were obtained by multiple logistic regression. Results: The prevalence of kidney dysfunction was 19.2% (210/1094). The 28-day and 90-day mortality were higher in patients with kidney dysfunction than in those without kidney dysfunction (12.4% vs. 4.4%, P < 0.001; 19.0% vs. 8.5%, P < 0.001, respectively). Eighty percent (32/40) of non-survivor was associated with the presence of ACLF and 18 out of 32 patients (56.2%) were ACLF development after admission. In multiple logistic regression, low albumin level (0.1 mg/dL increase, OR 0.90, 95% CI 0.81-0.99, P = 0.033) and the presence of ACLF (at admission, HR 11.4, 95% CI 3.8-33.6, P < 0.001; after admission, HR 30.8, 95% CI 9.9-95.8, P < 0.001) had independent factors of 90-day mortality. Especially, ACLF experience of grade 2 or above had higher mortality than grade 1 ACLF (P < 0.001). Conclusions: In cirrhotic patients without kidney failure, kidney dysfunction with acute deterioration had a substantial mortality. To improve the mortality, it is necessary to endeavor to recognize the early renal dysfunction and to prevent additional organ failure and the progression of ACLF.
Management of viral hepatitis in Liver transplant recipients
( Soung Won Jeong ),( Young Rok Choi ),( Jin Wook Kim ) 대한간학회 2014 Clinical and Molecular Hepatology(대한간학회지) Vol.20 No.4
Recurrence of viral hepatitis after liver transplantation (LT) can progress to graft failure and lead to a decrease in longterm survival. Recently, there have been remarkable improvement in the treatment of chronic hepatitis B (CHB) using potent antiviral agents. Combination of hepatitis B immunoglobulin and potent antiviral therapy has brought marked advances in the management of CHB for liver transplant recipients. Post-transplant antiviral therapy for hepatitis C virus infection is generally reserved for patients showing progressive disease. Acheiving a sustained virological response in patients with LT greatly ameliorates graft and overall survival, however this only occurs in 30% of transplant recipient using pegylated interferon and ribavirin (RBV). Direct acting antivirals such as protease inhibitors, polymerase or other non-structural proteins inhibitors are anticipated to establish the new standard of care for transplant recipients. In liver transplant recipients, hepatitis E virus infection is an uncommon disease. However, it can lead to chronic hepatitis and cirrhosis and may require retransplantation. Recently, 3-month course of RBV monotherapy has been reported as an effective treatment. This review focuses on the recent management and therapeutic approaches of viral hepatitis in liver transplant recipient. (Clin Mol Hepatol 2014;20:338-344)